Patents Assigned to Bayer Intellectual Property GmbH
-
Patent number: 11377417Abstract: The present application relates to novel 3-phenylpropionic acid derivatives which carry a branched or cyclic alkyl substituent in the 3-position, to processes for their preparation, to their use for the treatment and/or prevention of diseases and to their use for preparing medicaments for the treatment and/or prevention of diseases, in particular for the treatment and/or prevention of cardiovascular diseases.Type: GrantFiled: June 18, 2020Date of Patent: July 5, 2022Assignee: Bayer Intellectual Property GmbHInventors: Michael Hahn, Thomas Lampe, Johannes-Peter Stasch, Karl-Heinz Schlemmer, Frank Wunder, Volkhart Min-Jian Li, Eva Maria Becker-Pelster, Friederike Stoll, Andreas Knorr, Elisabeth Woltering
-
Patent number: 11371057Abstract: Present invention relates to the use of the ALS inhibitor herbicides for controlling unwanted vegetation in ALS inhibitor herbicide tolerant Beta vulgaris plants, more especially, present invention relates to the use of ALS inhibitor herbicides for control of unwanted vegetation in Beta vulgaris, preferably in sugar beet growing areas in which the Beta vulgaris, preferably sugar beet comprise a mutation in codon 1705-1707 of an endogenous ALS gene encoding an ALS protein containing an amino acid that is different from tryptophan at position 569, preferably the tryptophan is substituted by leucine.Type: GrantFiled: December 5, 2019Date of Patent: June 28, 2022Assignee: Bayer Intellectual Property GmbHInventors: Ruediger Hain, Gerhard Johann, Guenter Donn
-
Patent number: 11241010Abstract: The present invention relates to the use of succinate dehydrogenase Inhibitors for extending shelf life and storage stability of fruits and vegetables, to a method for extending shelf life of fruits and vegetables by applying a succinate dehydrogenase inhibitor to the crops prior to the harvest of the fruits or vegetables and to a fruit or vegetable treated with a succinate dehydrogenase Inhibitor.Type: GrantFiled: December 18, 2019Date of Patent: February 8, 2022Assignee: Bayer Intellectual Property GmbHInventors: Heiko Rieck, Helene Lachaise, Gilbert Labourdette, Peter Howard Davies, Dominique Steiger, Luk De Maeyer, George Hauley Musson, IV, Lorianne Fought, Sylvain Tafforeau
-
Patent number: 11202447Abstract: The invention relates to herbicidal compositions comprising an effective amount of an active ingredient combination composed of (a) at least one substituted thien-3-ylsulfonylamino(thio)carbonyl-triazolin(thi) one of the formula (I) in which R1, R2 and R3 are as defined in the description, —or salts of the compounds of the formula (I)— and (b) one or more compounds from a second group of herbicides which comprises selected 4-HPPD inhibitors, and, if desired, additionally (c) a crop plant tolerance promoter compound. The invention further relates to the use of the compositions for controlling unwanted plant growth and to a process for producing the compositions.Type: GrantFiled: August 13, 2013Date of Patent: December 21, 2021Assignee: Bayer Intellectual Property GmbHInventors: Markus Dollinger, Hans-Joachim Santel, Ernst Rudolf Gesing, Erwin Hacker
-
Patent number: 11147274Abstract: The present invention relates to active compound combinations, in particular within a fungicide composition, which comprises (A) a thiazolylisoxazoline of formula (I) and a further fungicidally active compound (B). Moreover, the invention relates to a method for curatively or preventively controlling the phytopathogenic fungi of plants or crops, to the use of a combination according to the invention for the treatment of seed, to a method for protecting a seed and not at least to the treated seed.Type: GrantFiled: March 29, 2019Date of Patent: October 19, 2021Assignee: Bayer Intellectual Property GmbHInventors: Ulrike Wachendorff-Neumann, Sebastian Hoffmann, Pierre Wasnaire
-
Patent number: 10865406Abstract: The present invention relates to an ALS inhibitor herbicide tolerant Beta vulgaris plant and parts thereof comprising a mutation of an endogenous acetolactate synthase (ALS) gene, wherein the ALS gene encodes an ALS polypeptide containing an amino acid different from tryptophan at a position 569 of the ALS polypeptide.Type: GrantFiled: October 13, 2011Date of Patent: December 15, 2020Assignees: BAYER INTELLECTUAL PROPERTY GMBH, KWS SAAT AGInventors: Ruediger Hain, Juergen Benting, Guenter Donn, Nathalie Knittel-Ottleben, Bernd Holtschulte, Andreas Loock, Clemens Springmann, Rudolf Jansen
-
Publication number: 20200385335Abstract: The present application relates to novel 3-phenylpropionic acid derivatives which carry a branched or cyclic alkyl substituent in the 3-position, to processes for their preparation, to their use for the treatment and/or prevention of diseases and to their use for preparing medicaments for the treatment and/or prevention of diseases, in particular for the treatment and/or prevention of cardiovascular diseases.Type: ApplicationFiled: June 18, 2020Publication date: December 10, 2020Applicant: Bayer Intellectual Property GmbHInventors: Michael Hahn, Thomas Lampe, Johannes-Peter Stasch, Karl-Heinz Schlemmer, Frank Wunder, Volkhart Min-Jian Li, Eva Maria Becker-Pelster, Friederike Stoll, Andreas Knorr, Elisabeth Woltering
-
Publication number: 20200377614Abstract: The present invention provides immunoconjugates composed of antibodies, e.g., monoclonal antibodies, or antibody fragments that bind to mesothelin, that are conjugated to cytotoxic agents, e.g., maytansine, or derivatives thereof, and/or co-administered or formulated with one or more additional anti-cancer agents. The immunoconjugates of the invention can be used in the methods of the invention to treat and/or diagnose and/or monitor cancers, e.g. solid tumors.Type: ApplicationFiled: August 17, 2020Publication date: December 3, 2020Applicant: Bayer Intellectual Property GmbHInventors: Antje KAHNERT, Kerstin UNTERSCHEMMANN, Iring HEISLER, Charlotte Christine KOPITZ, Joachim SCHUHMACHER
-
Patent number: 10781263Abstract: The present invention provides immunoconjugates composed of antibodies, e.g., monoclonal antibodies, or antibody fragments that bind to mesothelin, that are conjugated to cytotoxic agents, e.g., maytansine, or derivatives thereof, and/or co-administered or formulated with one or more additional anti-cancer agents. The immunoconjugates of the invention can be used in the methods of the invention to treat and/or diagnose and/or monitor cancers, e.g. solid tumors, recombinant antigen-binding regions and antibodies and functional fragments containing such antigen-binding regions that are specific for the membrane-anchored, 40 kDa mesothelin polypeptide, which is overexpressed in several tumors, such as pancreatic and ovarian tumors, mesothelioma and lung cancer cells.Type: GrantFiled: March 16, 2018Date of Patent: September 22, 2020Assignee: Bayer Intellectual Property GmbHInventors: Antje Kahnert, Kerstin Unterschemmann, Iring Heisler, Charlotte Christine Kopitz, Joachim Schuhmacher
-
Patent number: 10751361Abstract: The present invention relates to a method of immune activation which is effective for eliciting a non-antigen-specific immune response in a member of the bovine species. The method is particularly effective for protecting a member of the bovine species from infectious disease and treating animals inflicted with infectious disease.Type: GrantFiled: August 8, 2018Date of Patent: August 25, 2020Assignee: BAYER INTELLECTUAL PROPERTY GMBHInventors: Albert Abraham, Daniel Keil, Jason Nickell, Christian Weiss
-
Patent number: 10647779Abstract: The present invention provides immunoconjugates composed of antibodies, e.g., monoclonal antibodies, or antibody fragments that bind to mesothelin, that are conjugated to cytotoxic agents, e.g., maytansine, or derivatives thereof, and/or co-administered or formulated with one or more additional anti-cancer agents. The immunoconjugates of the invention can be used in the methods of the invention to treat and/or diagnose and/or monitor cancers, solid tumors, recombinant antigen-binding regions and antibodies and functional fragments containing such antigen-binding regions that are specific for the membrane-anchored, 40 kDa mesothelin polypeptide, which which is overexpressed in several tumors, such as pancreatic and ovarian tumors, mesothelioma and lung cancer cells.Type: GrantFiled: July 21, 2017Date of Patent: May 12, 2020Assignee: Bayer Intellectual Property GmbHInventors: Antje Kahnert, Kerstin Unterschemmann, Iring Heisler, Charlotte Kopitz, Joachim Schuhmacher
-
Patent number: 10604532Abstract: Compounds of formula (I) which are inhibitors of Bub 1 kinase, processes for their production and their use as pharmaceuticals.Type: GrantFiled: March 21, 2019Date of Patent: March 31, 2020Assignees: Bayer Intellectual Property GmbH, Bayer Pharma AktiengesellschaftInventors: Marion Hitchcock, Anne Mengel, Vera Pütter, Gerhard Siemeister, Antje Margret Wengner, Hans Briem, Knut Eis, Volker Schulze, Amaury Ernesto Fernandez-Montalvan, Stefan Prechtl, Simon Holton, Jörg Fanghänel, Philip Lienau, Cornelia Preusse, Mark Jean Gnoth
-
Patent number: 10548315Abstract: The present invention relates to the use of succinate dehydrogenase Inhibitors for extending shelf life and storage stability of fruits and vegetables, to a method for extending shelf life of fruits and vegetables by applying a succinate dehydrogenase inhibitor to the crops prior to the harvest of the fruits or vegetables and to a fruit or vegetable treated with a succinate dehydrogenase Inhibitor.Type: GrantFiled: February 12, 2010Date of Patent: February 4, 2020Assignee: BAYER INTELLECTUAL PROPERTY GMBHInventors: Heiko Rieck, Hélène Lachaise, Gilbert Labourdette, Pete Howard Davies, Dominique Steiger, Luk De Maeyer, George Hauley Musson, IV, Lorianne Fought, Sylvain Tafforeau
-
Patent number: 10544426Abstract: Present invention relates to the use of the ALS inhibitor herbicides for controlling unwanted vegetation in ALS inhibitor herbicide tolerant Beta vulgaris plants, more especially, present invention relates to the use of ALS inhibitor herbicides for control of unwanted vegetation in Beta vulgaris, preferably in sugar beet growing areas in which the Beta vulgaris, preferably sugar beet comprise a mutation in codon 1705-1707 of an endogenous ALS gene encoding an ALS protein containing an amino acid that is different from tryptophan at position 569, preferably the tryptophan is substituted by leucine.Type: GrantFiled: October 13, 2011Date of Patent: January 28, 2020Assignee: BAYER INTELLECTUAL PROPERTY GMBHInventors: Ruediger Hain, Gerhard Johann, Guenter Donn
-
Patent number: 10487079Abstract: The invention relates to novel heteroaryl carboxamides, processes for their preparation, and their use for producing medicaments for the treatment and/or prophylaxis of diseases and for improving perception, concentration, learning and/or memory.Type: GrantFiled: February 27, 2018Date of Patent: November 26, 2019Assignee: BAYER INTELLECTUAL PROPERTY GMBHInventors: Martin Hendrix, Frank-Gerhard Böß, Christina Erb, Joachim Krüger, Christoph Methfessel, Rudy Schreiber, Welf-Burkhard Wiese, Joachim Luithle
-
Patent number: 10463606Abstract: The invention is directed to the use of alternan as texturizing agent, particularly as fat or oil replacer in foodstuffs or cosmetic preparations, a homogeneous composition comprising alternan and water, the use of the homogeneous composition as texturizing agent in foodstuffs or cosmetic preparations, and foodstuffs and cosmetic preparations comprising alternan as texturizing agent or a homogeneous composition comprising alternan.Type: GrantFiled: May 19, 2016Date of Patent: November 5, 2019Assignee: BAYER INTELLECTUAL PROPERTY GMBHInventors: Claus Frohberg, Jens Pilling
-
Patent number: 10463666Abstract: The present invention relates to a pharmaceutical composition which comprises progestogens, preferably drospirenone, estrogens, preferably ethinylestradiol and 5-methyl-(6S)-tetrahydrofolate, can be employed as oral contraceptive and moreover prevents disorders caused by folate deficiency in the consumers, in particular cardiovascular disorders and, after conception of the embryo, congenital malformations caused by folate deficiency such as, for example, neural tube defects, ventricular valve defects, urogenital defects, and cleft lip, jaw and palate, without masking the symptoms of vitamin B12 deficiency, and at the same time even in the case of homozygous or heterozygous polymorphism of methylenetetrahydrofolate reductase facilitates unimpaired utilizability of the folate component 5-methyl-(6S)-tetrahydrofolate by the body and thus its biological activity for preventing the abovementioned congenital malformations caused by folate deficiency.Type: GrantFiled: December 10, 2015Date of Patent: November 5, 2019Assignees: MERCK & CIE, Bayer Intellectual Property GmbHInventors: Kai Strothmann, Gavin Welch Wasserfall-Smith, Klaus Pietrzik, Kristina King, Rudolf Moser
-
Patent number: 10433550Abstract: The present invention relates to active compound combinations for reducing the damage of plants and plant parts as well as losses in harvested fruits or vegetables caused by insects, nematodes or phytopathogens and which have fungicidal or nematicidal or insecticidal activity including any combination of the three activities, in particular within a composition, which comprises (A) Fluopyram, (B) a spore-forming bacterium of the genera Bacillus, selected from Bacillus firmus, Bacillus cereus, Bacillus pumilis, Bacillus amyloliquefaciens, Bacillus subtilis strain GB03, Bacillus subtilis strain QST713, and (C) at least one biological control agent, in particular bacteria, fungi or yeasts, protozoa, viruses, entomopathogenic nematodes, inoculants, botanicals and products produced by microorganisms including proteins or secondary metabolites.Type: GrantFiled: June 7, 2016Date of Patent: October 8, 2019Assignees: BAYER INTELLECTUAL PROPERTY GMBH, BAYER CROPSCIENCE AGInventors: Elke Hellwege, Heike Hungenberg
-
Patent number: 10435417Abstract: A process for producing high-purity gadobutrol in a purity (according to HPLC) of more than 99.7 or 99.8 or 99.9% and the use for preparing a pharmaceutical formulation for parenteral administration is described. The process is carried out using specifically controlled crystallization conditions.Type: GrantFiled: July 31, 2017Date of Patent: October 8, 2019Assignee: BAYER INTELLECTUAL PROPERTY GMBHInventors: Johannes Platzek, Wilhelm Trentmann
-
Patent number: D934414Type: GrantFiled: April 29, 2018Date of Patent: October 26, 2021Assignee: Bayer Intellectual Property GmbHInventor: Bruno Chazel